Of all malignant eyelid lesions 90% are basal cell carcinomas. The lower lids are the primary area of involvement in over 70% of cases, followed in relative frequency by the medial canthus, upper lid, and lateral canthus.' Characteristically, basal cell carcinomas are non-metastasising tumours which have, however, a great tendency to recur. Medial canthal lesions, which account for the second most common site of this tumour in its primary form, can spread deeply into the orbit and sinuses, eventually requiring exenteration for cure. A recurrence in this area can thus be especially devastating.
In treating eyelid tumours the considerations are many and varied. The usual principles of cancer surgery, to obtain an adequate margin of normal tissue about a malignancy, may partly give way to anxiety about cosmetic appearance and preservation of lacrimal and lid functions and their overall effects on the globe. Note the surrounding telangiectasis characteristic of a radiodermatitis. Fig. 2 shows the extent of surgery required to achieve a tumour free field. The lacrimal system had to be sacrificed but the globe was saved.
Case 2. Fig. 3 shows a recurrent postirradiated medial canthal basal cell carcinoma. This tumour is fixed to the underlying bone and distorts the canthal anatomy. To get to an area devoid of cancer cells not only was an exenteration required (the medial rectus and conjunctiva were also infiltrated with tumour) but part of the patient's nose and frontal bone had to be sacrificed (Fig. 4) .
Discussion
The clinician has a much better chance of totally eradicating a tumour by treating it aggressively in its primary, virgin state. The chance for successful long term cure after recurrence is considerably less. Irrespective of the mode of treatment, recurrence rates for primary lesions range from 1 to 8%. Kopf 
